Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Verve Therapeutics, Inc.

Verve Therapeutics is a clinical-stage biotechnology company created with a singular focus: to protect the world from heart disease. Founded by world-leading experts in cardiovascular medicine, human genetics and gene editing, the company aims to develop transformative, once-and-done therapies for coronary heart disease. Verve’s gene editing medicines are designed to safely edit the genome of adults and mimic naturally occurring gene variants to permanently lower LDL cholesterol and triglyceride levels. The company is advancing a pipeline of precision genetic medicines, led by VERVE-101, which is being developed initially for heterozygous familial hypercholesterolemia, a potentially fatal genetic heart disease. In 2023, Verve was recognized as a "Best Places to Work" by the Boston Globe. Verve is headquartered in Boston, Massachusetts. 

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue				1.94M -	11.76M 505.77%
cost of revenue					5.46M -
gross profit				1.94M -	6.30M 224.73%
selling and marketing expenses					-5.46M -
general and administrative expenses	2.50M -	5.26M 110.41%	18.86M 258.92%	37.53M 98.96%	49.94M 33.05%
selling general and administrative expenses	2.50M -	5.26M 110.41%	18.86M 258.92%	37.53M 98.96%	44.48M 18.51%
research and development expenses	11.14M -	35.37M 217.40%	68.20M 92.82%	130.09M 90.75%	184.95M 42.16%
other expenses	-5.93M -	-5.24M 11.70%	-33.39M 537.32%	1.49M 104.45%	165K 88.90%
cost and expenses	13.64M -	40.63M 197.81%	87.07M 114.31%	167.63M 92.53%	234.88M 40.12%
operating expenses	13.64M -	40.63M 197.81%	87.07M 114.31%	167.63M 92.53%	229.43M 36.87%
interest expense				-8.35M -
ebitda	-13.54M -	-39.30M 190.33%	-87.07M 121.55%	-162.88M 87.08%	-217.67M 33.64%
operating income	-13.64M -	-40.63M 197.81%	-87.07M 114.31%	-165.69M 90.30%	-223.12M 34.67%
depreciation and amortization	106K -	1.33M 1,152.83%	1.53M 15.59%	2.80M 82.67%	5.46M 94.54%
total other income expenses net	-5.66M -	-5.08M 10.22%	-33.25M 554.86%	8.35M 125.12%	23.33M 179.31%
income before tax	-19.30M -	-45.70M 136.85%	-120.31M 163.25%	-157.33M 30.77%	-199.79M 26.99%
income tax expense	-278K -	-162K 41.73%	-1.68M 935.19%	53K 103.16%	275K 418.87%
net income	-19.02M -	-45.54M 139.46%	-118.64M 160.50%	-157.39M 32.66%	-200.07M 27.12%
weighted average shs out	17.74M -	17.74M 0%	26.87M 51.48%	17.74M 33.99%	64.18M 261.76%
weighted average shs out dil	17.74M -	17.74M 0%	26.87M 51.48%	17.74M 33.99%	64.18M 261.76%
eps	-1.07 -	-2.57 140.19%	-4.41 71.60%	-8.87 101.13%	-3.12 64.83%
epsdiluted	-1.07 -	-2.57 140.19%	-4.41 71.60%	-8.87 101.13%	-3.12 64.83%

COM:VERVETX

Vervet Logic, Inc.

Last Close

4.60

22/11 21:00

Market Cap

507.99M

Beta: -

Volume Today

1.12M

Avg: -

Preview